AR113224A1 - Conjugados de anticuerpo que comprenden un agonista de sting - Google Patents
Conjugados de anticuerpo que comprenden un agonista de stingInfo
- Publication number
- AR113224A1 AR113224A1 ARP180101063A ARP180101063A AR113224A1 AR 113224 A1 AR113224 A1 AR 113224A1 AR P180101063 A ARP180101063 A AR P180101063A AR P180101063 A ARP180101063 A AR P180101063A AR 113224 A1 AR113224 A1 AR 113224A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody conjugates
- sting agonist
- conjugates including
- immunoconjugates
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
Abstract
Se proporcionan en la presente inmunoconjugados que comprenden agonistas de STING. También se dan a conocer métodos para producir los inmunoconjugados y métodos de tratamiento del cáncer usando los inmunoconjugados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762491879P | 2017-04-28 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113224A1 true AR113224A1 (es) | 2020-02-19 |
Family
ID=62165655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101063A AR113224A1 (es) | 2017-04-28 | 2018-04-25 | Conjugados de anticuerpo que comprenden un agonista de sting |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3615080A1 (es) |
JP (1) | JP2020517700A (es) |
CN (1) | CN110799218A (es) |
AR (1) | AR113224A1 (es) |
WO (1) | WO2018200812A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
EP3505188A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Pro-cyclic dinucleotide conjugates for cytokine induction |
BR112020022299A2 (pt) | 2018-05-09 | 2021-02-23 | Legochem Biosciences, Inc. | composições e métodos relacionados a conjugados de anticorpo-fármaco anti-cd19 |
CA3101623A1 (en) * | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods for the treatment of bladder cancer |
WO2020014127A1 (en) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
CN113348181A (zh) * | 2018-10-31 | 2021-09-03 | 诺华股份有限公司 | 包含sting激动剂的dc-sign抗体缀合物 |
WO2020089815A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
PE20211296A1 (es) * | 2018-12-21 | 2021-07-20 | Novartis Ag | Anticuerpos anti-pmel17 y conjugados de los mismos |
MA55805A (fr) * | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
AU2020267486A1 (en) | 2019-05-09 | 2021-11-11 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as STING modulators |
SG11202112223XA (en) | 2019-05-10 | 2021-12-30 | Takeda Pharmaceuticals Co | Antibody drug conjugates |
PE20220218A1 (es) | 2019-05-20 | 2022-02-02 | Novartis Ag | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso |
AU2020315802A1 (en) | 2019-07-19 | 2022-02-24 | ImmuneSensor Therapeutics Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
CN114585623A (zh) | 2019-08-02 | 2022-06-03 | 梅尔莎纳医疗公司 | 双[N-((5-氨基甲酰基)-1H-苯并[d]咪唑-2-基)吡唑-5-甲酰胺]衍生物和相关化合物作为STING(干扰素基因刺激物)激动剂用于治疗癌症 |
MX2022002152A (es) * | 2019-08-21 | 2022-05-18 | Scripps Research Inst | Agonistas biciclicos del estimulador de genes de interferon sting. |
KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
WO2021046426A1 (en) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies |
US20230074385A1 (en) * | 2019-12-23 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Method for producing eribulin-based antibody-drug conjugate |
US20230330248A1 (en) * | 2020-03-06 | 2023-10-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
MX2022012304A (es) * | 2020-04-02 | 2022-11-30 | Mersana Therapeutics Inc | Conjugados de anticuerpo-farmaco que comprenden agonistas de sting. |
EP4134098A1 (en) | 2020-04-10 | 2023-02-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
WO2021216572A1 (en) | 2020-04-20 | 2021-10-28 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
CA3178464A1 (en) | 2020-05-15 | 2021-11-18 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with immune checkpoint inhibitors |
CN111592570B (zh) * | 2020-05-15 | 2022-04-29 | 清华大学 | 新型sting激动剂及其制备方法和应用 |
PE20231947A1 (es) | 2020-11-09 | 2023-12-05 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco |
EP4319820A1 (en) | 2021-04-10 | 2024-02-14 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023004440A2 (en) | 2021-07-23 | 2023-01-26 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
WO2023109942A1 (en) * | 2021-12-17 | 2023-06-22 | Jacobio Pharmaceuticals Co., Ltd. | Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof |
WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
JP5769616B2 (ja) | 2008-04-30 | 2015-08-26 | イミュノジェン・インコーポレーテッド | クロスリンカーおよびそれらの使用 |
US10022256B2 (en) | 2012-11-30 | 2018-07-17 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
ES2718910T3 (es) | 2012-12-13 | 2019-07-05 | Aduro Biotech Inc | Composiciones que comprenden dinucleótidos cíclicos de purina que tienen estereoquímicas definidas y métodos para su preparación y uso |
AU2014214751B2 (en) * | 2013-02-08 | 2017-06-01 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
CA2908154C (en) | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
US10092644B2 (en) | 2013-11-22 | 2018-10-09 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
SG11201609021QA (en) | 2014-06-04 | 2016-11-29 | Glaxosmithkline Ip Dev Ltd | Cyclic di-nucleotides as modulators of sting |
DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
SG11201706756VA (en) * | 2015-03-10 | 2017-09-28 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
WO2016161372A1 (en) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
CN107922455A (zh) | 2015-07-02 | 2018-04-17 | 春季银行制药股份有限公司 | 用于治疗病毒感染的组合物和方法 |
TW201717968A (zh) | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導rig-i和其他模式辨識受體之化合物及組成物 |
EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
BR112018002757A8 (pt) | 2015-08-13 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio |
EP3386536A4 (en) * | 2015-12-07 | 2019-07-31 | Opi Vi- IP Holdco LLC | COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF |
CN106540256A (zh) * | 2016-03-27 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 |
TW201803886A (zh) | 2016-07-06 | 2018-02-01 | 史貝羅威生物科學有限公司 | 化合物、組合物及用於治療疾病之方法 |
JP7100227B2 (ja) | 2016-07-06 | 2022-07-13 | エフ-スター・セラピューティクス・インコーポレイテッド | 疾患の治療のための化合物、組成物、および方法 |
CR20190071A (es) | 2016-07-15 | 2019-10-29 | Sperovie Biosciences Inc | Compuestos, composiciones y métodos para el tratamiento de enfermedades |
WO2018013887A1 (en) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
-
2018
- 2018-04-25 AR ARP180101063A patent/AR113224A1/es unknown
- 2018-04-26 EP EP18724677.2A patent/EP3615080A1/en not_active Withdrawn
- 2018-04-26 CN CN201880043438.4A patent/CN110799218A/zh active Pending
- 2018-04-26 JP JP2019558397A patent/JP2020517700A/ja active Pending
- 2018-04-26 WO PCT/US2018/029570 patent/WO2018200812A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2020517700A (ja) | 2020-06-18 |
CN110799218A (zh) | 2020-02-14 |
WO2018200812A1 (en) | 2018-11-01 |
EP3615080A1 (en) | 2020-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR113224A1 (es) | Conjugados de anticuerpo que comprenden un agonista de sting | |
ECSP18038868A (es) | Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll | |
CL2018003406A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo. | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
CL2019003050A1 (es) | Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinación. | |
CO2017010618A2 (es) | Anticuerpos contra icos | |
CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
ECSP19072235A (es) | Anticuerpos anti-ILT4 y fragmentos de unión a antígeno | |
CO2017004782A2 (es) | Conjugados de anticuerpo- farmaco | |
CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CL2016002667A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
NI201700016A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
CL2019003168A1 (es) | Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos. | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
CY1124230T1 (el) | Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου | |
CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
UY38433A (es) | Conjugados de anticuerpo dc–sign que comprenden agonistas de sting | |
BR112017026027A2 (pt) | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 | |
BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
CO2018005393A2 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos | |
CL2018002050A1 (es) | Conjugados anticuerpo-fármaco dirigidos a gcc. | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
CO2017010692A2 (es) | Construcciones de calicheamicina y sus métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |